Carla L Alves

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 7

Top Venues

International journal of molecular sciences

Nature communications

Breast cancer research : BCR

NPJ breast cancer

Syddansk Universitet (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Syddansk Universitet Dec 01 2013

Denmark

PHD :: Cancer and Inflammation Research, IMM

Publications

Carla L Alves, Henrik Jørn Ditzel
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International journal of molecular sciences 24 (5) (2023)
Carla L Alves, Henrik Jørn Ditzel
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International journal of molecular sciences 24 (5) (2023)
Carla L Alves, Henrik Jørn Ditzel
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International journal of molecular sciences 24 (5) (2023)
Sanne Løkkegaard, Daniel Elias, Carla L Alves, Martin V Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F Gjerstorff, Lene E Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S Lindström, Laura J Esserman, Anne E Lykkesfeldt, Jens S Andersen, Rikke Leth-Larsen, Henrik Jørn Ditzel
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. NPJ breast cancer 7 (1) (2021)
Carla L Alves, Sidse Ehmsen, Mikkel G Terp, Neil Portman, Martina Tuttolomondo, Odd L Gammelgaard, Monique F Hundebøl, Kamila Kaminska, Lene E Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik Jørn Ditzel
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature communications 12 (1) (2021)
Carla L Alves, Sidse Ehmsen, Mikkel G Terp, Neil Portman, Martina Tuttolomondo, Odd L Gammelgaard, Monique F Hundebøl, Kamila Kaminska, Lene E Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik Jørn Ditzel
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nature communications 12 (1) (2021)
Carla L Alves, Daniel Elias, Maria B Lyng, Martin Bak, Henrik Jørn Ditzel
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast cancer research : BCR 20 (1) (2018)

Carla L Alves.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Carla L Alves